Back to Journals » OncoTargets and Therapy » Volume 7

Microtubule inhibitor-based antibody–drug conjugates for cancer therapy

Authors Klute K, Nackos E, Tasaki S, Nguyen D, Bander N, Tagawa S

Received 24 June 2014

Accepted for publication 20 August 2014

Published 3 December 2014 Volume 2014:7 Pages 2227—2236

DOI https://doi.org/10.2147/OTT.S46887

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Dr Faris Farassati


Kelsey Klute,1,* Eleni Nackos,1,* Shinsuke Tasaki,1 Daniel P Nguyen,2 Neil H Bander,2 Scott T Tagawa1,2

1Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY, USA; 2Department of Urology, Weill Cornell Medical College, New York, NY, USA

*These authors contributed equally to this work

Abstract: The specificity of monoclonal antibodies represents a potential therapeutic advantage, but their use as single agents in oncology has proven limited to date. The development of antibody-drug conjugates (ADCs) takes advantage of the specificity of the monoclonal antibody and potent cytotoxic effect of chemotherapy, leading to enhanced cytotoxicity in target cells and limiting toxicity to normal tissue. Microtubules represent a validated oncologic target in a range of tumor types, with a number of anti-microtubule targeting cytotoxic drugs approved for cancer use. The systemic use of potent microtubule-binding agents is limited by their effects in normal cells, which leads to toxicity including myelosuppression and peripheral neuropathy. Linking these agents to monoclonal antibodies may limit toxicity to normal tissues and increase drug concentration in target tissues, also allowing the use of more potent agents which would be too toxic to administer in their unbound form. Two such ADCs have been approved for clinical use and many others are in development. Here we review the characteristics of each of the ADC components that have led to efficacious therapies and discuss some of the tubulin inhibitor-based ADCs in development for cancer therapy.

Keywords: monoclonal antibody, antibody–drug conjugate, microtubule inhibitor

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]